4 stories
Clinical trial coverage is the cross-cutting tag for trial readouts that don't fit a more specific bucket. The detailed Phase 1/2/3 work shows up under #phase-3, #clinical-trials, and the named trial tags.
What lands here: cross-portfolio readouts, comparative analyses, real-world-evidence studies that supplement trial data, and the clinical-trial monitoring and regulatory-modernization stories that affect how trials get run. The 2026 FDA push on real-time data and clinical-trial monitoring updates appears here, as does the broader infrastructure work on adaptive trials and decentralized designs.
Stories here cover trial-design news, cross-portfolio analyses, and regulatory modernization. See #real-world-evidence for routine-care analyses.
A 16-week randomized, double-blind trial of oral semaglutide in 72 adults with major depressive disorder found no improvement in executive function vs placebo. However, secondary analyses showed semaglutide improved global cognition and produced clinically significant weight loss, suggesting potential but unclear neuropsychiatric benefit.
UC launched a clinical trial using Peptilogics' peptide-based antimicrobial agent to treat prosthetic joint infections by targeting bacterial biofilms that have resisted traditional therapies.
The ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable semaglutide or tirzepatide to oral orforglipron maintained their weight loss.
Oral peptide icotrokinra delivered complete skin clearance through week 52 with a strong safety profile in the ICONIC-ADVANCE trials, presented at the American Academy of Dermatology meeting.